| Literature DB >> 27437539 |
Sung Chul Kam1, Sang Hoon Lee2, Ju Hong Jeon3, Insuk So4, Mee Ree Chae5, Jong Kwan Park6, Sung Won Lee5.
Abstract
PURPOSE: To investigate the effects of cavernous nerve injury (CNI) on gene expression profiles in the cavernosal tissue of a CNI-induced erectile dysfunction (ED) model and to provide a basis for future investigations to discover potential target genes for ED treatment.Entities:
Keywords: Erectile dysfunction; Gene expression; Microarray analysis; Peripheral nerve injuries
Mesh:
Year: 2016 PMID: 27437539 PMCID: PMC4949699 DOI: 10.4111/icu.2016.57.4.286
Source DB: PubMed Journal: Investig Clin Urol ISSN: 2466-0493
Fig. 1Representative records of data and intracavernosal pressure/ blood pressure (ICP/BP) from electric field stimulation at 12 weeks after cavernous nerve injury (CNI). Representative time course of changes in ICP for sham operation group rats (A), cavernous nerve (CN) crushing injury group rats (B), and summary of all in vivo data (C). In vivo experiments were performed 12 weeks after CNI in rats. *p-value<0.05, response significantly different compared with sham operation group.
Summary of data set information and the result of supervised classification analysis
| GSE31247 | GSE2457 | |
|---|---|---|
| No. of samples | 6 (3 normal and 3 CNI-induced ED model) | 10 (5 normal and 5 diabetes-induced ED model) |
| Total number of probe sets | 41,012 | 15,923 |
| No. of genes or probe sets after normalization and excluding missing gene annotations | 19,550 Probe sets | 9,180 Genes |
| No. of features selected on ReliefF 'average merit' >0.1 | 2,970 Probe sets | 2,595 Genes |
| Predictive accuracy | ||
| Before feature selection | 50% (2 CNI and 1 CNI-induced ED samples misclassified) | 70% (3 control samples misclassified) |
| After feature selection | 100% | 100% |
CNI, cavernous nerve injury; ED, erectile dysfunction.
Fig. 2Different gene expression patterns between normal and diabetes- or cavernous nerve injury (CNI)-induced erectile dysfunction (ED) penile tissues. (A) Unsupervised hierarchical clustering of gene expression profile distinguishes the CNI-induced ED model from (B) the diabetes-induced ED model. (C, D) Principal component analysis (PCA) plots for the CNI-induced and diabetes-induced model data. The sum of % variance is shown for each PCA plot. The diabetic-induced ED (DIED) data is taken from GSE2457 [10]. SON, sham operation normal tissue; NCT, normal cavernous tissue.
The list of 7 gene signatures significantly down-regulated in cavernous nerve injury-induced erectile dysfunction model (GSE31247)
| Name | ESa | NESb | Nominal p-value | FDR q-valuec |
|---|---|---|---|---|
| REPRODUCTIVE_PROCESS | –0.452 | –1.613 | 0.029 | 0.338 |
| POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY | –0.422 | –1.574 | 0.034 | 0.364 |
| ANATOMICAL_STRUCTURE_DEVELOPMENT | –0.296 | –1.633 | 0.006 | 0.367 |
| SYSTEM_DEVELOPMENT | –0.265 | –1.443 | 0.042 | 0.373 |
| CELLULAR_CATABOLIC_PROCESS | –0.387 | –1.423 | 0.109 | 0.386 |
| NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS | –0.442 | –1.661 | 0.013 | 0.399 |
| PROTEIN_METABOLIC_PROCESS | –0.266 | –1.445 | 0.043 | 0.399 |
The values of enrichment score (ES), normalized enrichment score (NES), nominal p-value, and false discovery rate (FDR) q-value were rounded off to 3 decimal places. The table is sorted smallest to largest by NES.
a:The ES indicates the degree to which a gene set is overrepresented at the entired ranked gene list. b:The NES was calculated by normalizing the enrichment score (ES) to account for the size of each gene signature. c:FDR q-value: FDR is to control the proportion of false positives corresponding to each NES. FDR was represented as q-value, which is the analog of p-value that has been corrected for multiple hypothesis testing.
The list of 33 gene signatures significantly up- or down-regulated in diabetes-induced erectile dysfunction model (GSE2457)
| Name | ESa | NESb | Nominal p-value | FDR q-valuec |
|---|---|---|---|---|
| SYSTEM_PROCESS | –0.441 | –2.124 | 0.000 | 0.003 |
| SKELETAL_DEVELOPMENT | –0.550 | –1.973 | 0.002 | 0.033 |
| ION_TRANSPORT | –0.482 | –1.854 | 0.002 | 0.066 |
| CATION_TRANSPORT | –0.485 | –1.760 | 0.002 | 0.113 |
| MONOVALENT_INORGANIC_CATION_TRANSPORT | –0.515 | –1.700 | 0.012 | 0.147 |
| CELL_CELL_SIGNALING | –0.356 | –1.663 | 0.004 | 0.163 |
| NEUROLOGICAL_SYSTEM_PROCESS | –0.370 | –1.635 | 0.006 | 0.174 |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | –0.371 | –1.591 | 0.013 | 0.189 |
| METAL_ION_TRANSPORT | –0.458 | –1.565 | 0.040 | 0.203 |
| SENSORY_PERCEPTION | –0.423 | –1.597 | 0.035 | 0.203 |
| SYSTEM_DEVELOPMENT | –0.293 | –1.531 | 0.008 | 0.231 |
| TISSUE_DEVELOPMENT | –0.450 | –1.511 | 0.041 | 0.242 |
| TRANSMISSION_OF_NERVE_IMPULSE | –0.378 | –1.466 | 0.039 | 0.243 |
| DNA_METABOLIC_PROCESS | 0.446 | 1.827 | 0.002 | 0.287 |
| RNA_PROCESSING | 0.367 | 1.400 | 0.080 | 0.306 |
| REGULATION_OF_CELLULAR_METABOLIC_PROCESS | 0.284 | 1.406 | 0.031 | 0.307 |
| ACTIN_FILAMENT_BASED_PROCESS | 0.441 | 1.412 | 0.107 | 0.311 |
| REGULATION_OF_METABOLIC_PROCESS | 0.280 | 1.383 | 0.029 | 0.323 |
| NEGATIVE_REGULATION_OF_TRANSCRIPTION | 0.375 | 1.374 | 0.108 | 0.324 |
| ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.374 | 1.414 | 0.057 | 0.324 |
| POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION | 0.397 | 1.366 | 0.101 | 0.326 |
| REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT | 0.316 | 1.421 | 0.040 | 0.327 |
| RESPONSE_TO_ENDOGENOUS_STIMULUS | 0.368 | 1.425 | 0.060 | 0.339 |
| NEGATIVE_REGULATION_OF_METABOLIC_PROCESS | 0.320 | 1.342 | 0.083 | 0.344 |
| TRANSCRIPTION_DNA_DEPENDENT | 0.299 | 1.429 | 0.027 | 0.351 |
| REGULATION_OF_TRANSCRIPTION | 0.290 | 1.345 | 0.067 | 0.352 |
| TRANSCRIPTION | 0.284 | 1.432 | 0.014 | 0.367 |
| DNA_REPAIR | 0.425 | 1.467 | 0.053 | 0.369 |
| NEGATIVE_REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS | 0.352 | 1.322 | 0.123 | 0.373 |
| RNA_BIOSYNTHETIC_PROCESS | 0.299 | 1.451 | 0.017 | 0.376 |
| ACTIN_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS | 0.459 | 1.476 | 0.069 | 0.378 |
| RNA_SPLICING | 0.459 | 1.435 | 0.092 | 0.386 |
| MACROMOLECULAR_COMPLEX_ASSEMBLY | 0.343 | 1.484 | 0.033 | 0.394 |
The values of enrichment score (ES), normalized enrichment score (NES), nominal p-value, and false discovery rate (FDR) q-value were rounded off to 3 decimal places. The table is sorted smallest to largest by NES.
a:The ES indicates the degree to which a gene set is overrepresented at the entired ranked gene list. b:The NES was calculated by normalizing the ES to account for the size of each gene signature. c:FDR q-value: FDR is to control the proportion of false positives corresponding to each NES. FDR was represented as q-value, which is the analog of p-value that has been corrected for multiple hypothesis testing.
Fig. 3Enrichment plot of ANATOMICAL_STRUCTURE_DEVELOPMENT gene signatures. The square box indicates the leading edge subset and the heat map presents 39 genes of the leading edge subset. SON, sham operation normal tissue; CNI_ED, cavernous nerve injury-induced erectile dysfunction; FDR, false discovery rate is the estimated probability that a gene set with a given NES represents a false positive finding; ES, enrichment score; NES, normalized enrichment score.
The list of 39 LES genes in ANATOMICAL_STRUCTURE_DEVELOPMENT gene signature
| Probe set ID | Gene symbol | Description | Rank metric scorea | Running ESb | Fold changeb | q-valueb |
|---|---|---|---|---|---|---|
| A_43_P13335 | Forkhead box E1 (thyroid transcription factor 2) | –0.40 | –0.29 | 0.85 | 0.01 | |
| A_44_P370213 | Nucleolin | –0.40 | –0.28 | 0.85 | NA | |
| A_44_P167930 | Myelin-associated oligodendrocyte basic protein | –0.40 | –0.27 | 0.85 | 0.01 | |
| A_43_P13327 | Ubiquitin B | –0.41 | –0.27 | 0.85 | 0.01 | |
| A_43_P15339 | Paired-like homeodomain transcription factor 1 | –0.41 | –0.26 | 0.85 | 0.01 | |
| A_44_P292462 | Growth hormone releasing hormone receptor | –0.43 | –0.26 | 0.84 | 0.01 | |
| A_42_P482475 | Potassium large conductance calcium-activated channel, subfamily M, beta member 2 | –0.42 | –0.26 | 0.85 | 0.01 | |
| A_43_P11660 | Persephin | –0.43 | –0.25 | 0.84 | 0.01 | |
| A_43_P15245 | Natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) | –0.43 | –0.24 | 0.84 | 0.01 | |
| A_44_P397725 | Myelin oligodendrocyte glycoprotein | –0.43 | –0.23 | 0.84 | 0.01 | |
| A_42_P700817 | Apolipoprotein A-V | –0.44 | –0.22 | 0.84 | 0.01 | |
| A_42_P524577 | Reticulon 1 | –0.44 | –0.22 | 0.84 | 0.01 | |
| A_44_P552728 | Sine oculis homeobox homolog 1 (Drosophila) | –0.45 | –0.22 | 0.84 | 0.01 | |
| A_44_P274021 | Myosin, heavy chain 11, smooth muscle | –0.45 | –0.21 | 0.83 | 0.01 | |
| A_44_P556319 | Fibroblast growth factor 18 | –0.48 | –0.21 | 0.83 | 0.01 | |
| A_44_P238421 | Collagen, type I, alpha 1 | –0.51 | –0.21 | 0.82 | 0.01 | |
| A_42_P741139 | Proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2, uncomplicated) | –0.46 | –0.20 | 0.95 | NA | |
| A_44_P557217 | Cystatin E/M | –0.48 | –0.20 | 0.82 | 0.01 | |
| A_42_P758492 | Paired-like homeodomain transcription factor 3 | –0.51 | –0.19 | 0.82 | 0.01 | |
| A_43_P13141 | RAS guanyl releasing protein 4 | –0.54 | –0.19 | 0.81 | 0.01 | |
| A_44_P447394 | SRY (sex determining region Y)-box 10 | –0.51 | –0.18 | 0.81 | 0.01 | |
| A_42_P532103 | Annexin A2 | –0.54 | –0.18 | 0.81 | 0.01 | |
| A_44_P527089 | Calcitonin/calcitonin-related polypeptide, alpha | –0.55 | –0.17 | 0.78 | NA | |
| A_44_P473020 | Histone deacetylase 5 | –0.55 | –0.15 | 0.80 | 0.01 | |
| A_43_P13057 | BAI1-associated protein 2 | –0.56 | –0.15 | 0.80 | 0.01 | |
| A_43_P10382 | Slit homolog 1 (Drosophila) | –0.59 | –0.15 | 0.79 | 0.01 | |
| A_42_P462771 | CD9 molecule | –0.60 | –0.14 | 0.79 | 0.01 | |
| A_42_P564712 | TAO kinase 2 | –0.61 | –0.13 | 0.78 | 0.01 | |
| A_44_P255236 | Actin, alpha 1, skeletal muscle | –0.61 | –0.11 | 0.69 | 0.01 | |
| A_43_P11733 | Peroxisome proliferative activated receptor, delta | –0.72 | –0.10 | 0.68 | 0.01 | |
| A_44_P1042234 | Stathmin-like 3 | –0.62 | –0.10 | 0.72 | 0.01 | |
| A_44_P395788 | Wingless-type MMTV integration site family, member 7A | –0.65 | –0.09 | 0.77 | 0.01 | |
| A_43_P13136 | Fibroblast growth factor 3 (murine mammary tumor virus integration site (v-int-2) oncogene homolog) | –0.73 | –0.09 | 0.75 | 0.01 | |
| A_43_P12245 | Ras homolog gene family, member B | –0.75 | –0.07 | 0.74 | 0.01 | |
| A_43_P11583 | Epithelial membrane protein 1 | –0.76 | –0.05 | 0.70 | 0.01 | |
| A_44_P230712 | RAS p21 protein activator (gtpase activating protein) 1 | –0.76 | –0.04 | 0.74 | 0.01 | |
| A_43_P16155 | V-raf murine sarcoma viral oncogene homolog B1 | –0.77 | –0.02 | 0.73 | 0.01 | |
| A_44_P458021 | Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) | –0.83 | –0.01 | 0.61 | 0.01 | |
| A_44_P337311 | Thrombospondin 4 | –0.85 | 0.01 | 0.64 | 0.01 |
The values of Rank metric score, running enrichment score (ES), fold change and p-value were rounded off to 2 decimal places. The table is sorted smallest to largest by running ES.
a:Score used to position the gene in the ranked list. b:The enrichment score at this point in the ranked list of genes. c:Fold change and q-value were calculated from significance analysis of microarrays analysis.
Fig. 4Differentially expressed genes in cavernous nerve injury (CNI)- and diabetes-induced erectile dysfunction (ED) models identified by analysis of microarrays (SAM) analysis. Volcano plots depicted the magnitude of fold change and significance of p-value of the genes identified by SAM in CNI- (A) or diabetes-induced ED (B) models. The x-axis represents log2 fold change and the y-axis log10 p-value. (C) Forty-six genes were commonly up-regulated, and (D) 77 genes were commonly down-regulated in CNI- and diabetes-induced ED models. The diabetic-induced ED data is taken from GSE2457 [10].